Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Serogroup B Meningococcal Disease Outbreaks

In certain outbreaks, vaccination against meningococcal disease is recommended to help stop the disease from spreading. However, until recently, there were no serogroup B meningococcal vaccines licensed for use in the United States.

Serogroup B meningococcal vaccination is recommended for people 10 years and older at increased risk for meningococcal disease, including people identified to be at increased risk because of a serogroup B meningococcal disease outbreak. Clinicians can use serogroup B meningococcal vaccines for people 10 through 25 years old consistent with the labeled indication.

Based on CDC’s interim guidance, this vaccine can be an important tool for controlling outbreaks of serogroup B meningococcal disease in organizational settings.